However, the relationship between EGFR mutations and Gefitinib target genes (FBP1, SBK1, and AURKA) warrants further investigation, and cancer tissues were collected to confirm the relationship between the risk model and nomogram and the prognosis of LUAD patients in the future. This evidence concerns the gene EGFR and cancer.